Treating Life-Threatening Bleedings - 1st Edition - ISBN: 9780128124390, 9780128124406

Treating Life-Threatening Bleedings

1st Edition

Development of Recombinant Coagulation Factor VIIa

Authors: Ulla Hedner
eBook ISBN: 9780128124406
Paperback ISBN: 9780128124390
Imprint: Academic Press
Published Date: 6th July 2017
Page Count: 214
Sales tax will be calculated at check-out Price includes VAT/GST
25% off
25% off
25% off
25% off
25% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
86.32
64.74
64.74
64.74
64.74
64.74
69.06
69.06
73.95
55.46
55.46
55.46
55.46
55.46
59.16
59.16
62.95
47.21
47.21
47.21
47.21
47.21
50.36
50.36
79.95
59.96
59.96
59.96
59.96
59.96
63.96
63.96
Unavailable
Price includes VAT/GST
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Description

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work.

The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

Key Features

  • Documents the successful roadmap of the development of a new concept of treating major bleedings in the most life-threatening situations
  • Stresses the importance of the close connection between the clinic and research, describing how a new concept of hemostasis was revealed by careful clinical observation
  • Offers real-world research and development context for drug discovery, and for the treatment of hemophilia and other bleeding disorders

Readership

Residents, fellows and professionals in hematology, pathology, surgery, internal/hospital medicine, public health

Table of Contents

About the Author
Preface and Acknowledgments

1. Classical Bleeding Disease (Hemophilia)
2. My Encounter With Hemophilia (1959-82)
3. The First Years at Novo Nordisk
4. The Development of Recombinant FVIIa (rFVIIa) (1985-88)
5. The Further Use and Development of rFVIIa (1989-96)
6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors
7. Treatment With rFVIIa in Malmö (1996-99)
8. The Launching and Uses of rFVIIa
9. Mechanism of Action and Dosage
10. The Continued Development of rFVIIa During the 2000s
11. Safety and Health Economy of rFVIIa
12. Three Different Descriptions of How rFVIIa Was Developed
13. Some Final Remarks
Index

Details

No. of pages:
214
Language:
English
Copyright:
© Academic Press 2017
Published:
Imprint:
Academic Press
eBook ISBN:
9780128124406
Paperback ISBN:
9780128124390

About the Author

Ulla  Hedner

Ulla Hedner

Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark.

Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983 . Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.

Affiliations and Expertise

Emeritus Professor, University of Lund, Lund, Sweden

Ratings and Reviews